Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Prospects for assessing the level of tissue IgE and the use of biological therapy in children with polypous rhinosinusitis
https://doi.org/10.21508/1027-4065-2024-69-4-11-15
Abstract
The review describes the mechanism of T2 inflammation and its relationship with chronic polypous rhinosinusitis. The authors conducted a search and systematization of data on the treatment of polypous rhinosinusitis using monoclonal antibodies that act on various biomarkers, and touched upon the problem of local IgE inflammation in the nasal mucosa.
Keywords
children,
chronic polypous rhinosinusitis,
biological therapy,
monoclonal antibodies,
tissue IgE level
Supporting agencies: The authors of this article confirmed the lack of conflict of interest and financial support, which should be reported
About the Authors
E. I. Shabelnikova
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
A. N. Pampura
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
A. I. Asmanov
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
N. D. Pivneva
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. Piskunov G.Z., Moiseeva Yu.P. Polypous rhinosinusitis, 2<sup>nd</sup> ed., add. M.: MEDpressinform 2021; 136 s. (in Russ.)
2. Ryazancev S.V. Clinical recommendations “Polypous rhinosinusitis”. Moskva—Sankt-Peterburg. 2014; 20 s. (in Russ.)
3. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58(Suppl S29): 1–464. DOI: 10.4193/Rhin20.600
4. Dunican E.M., Fahy J.V. The role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am ThoracSoc 2015; 12 (Suppl 2): 144–149. DOI: 10.1513/AnnalsATS.201506-377AW
5. Gevaert P., Wong K., Millette L.A., Carr T.F. The Role of IgE in Upper and Lower Airway Disease: More Than Just Allergy! Clinic Rev Allerg Immunol 2022; 62: 200–215. DOI: 10.1007/S12016–021–08901–1
6. Piskunov G.Z. Clinical recommendations “Polypous rhinosinusitis”. Russian Society of Rhinologists 2022–2025; 57. (in Russ.) http://rhinology.ru/wp-content/uploads/2022/10/ПРС-Клинические_рекомендации_финал.pdf
7. Li T., Yin J., Yang Y., Wang G., Zhang Y., Song X. Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives. Expert Rev Clin Immunol 2023; 19(8): 939–948. DOI: 10.1080/1744666x.2023.2231150
8. Schmale I., Poulakis A., Abend A., Luitje M., Man L. Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab: Real-World Use and Outcomes. J Allergy Clin Immunol Pract 2023; 11(10): 3203–3210. DOI: 10.1016/j.jaip.2023.07.038
9. Wu Q., Zhang Y., Kong W., Wang X., Yuan L., Zheng R. et al. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis. Int Arch Allergy Immunol 2022; 183(3): 279–288. DOI: 10.1159/000519228
10. Meltzer E., Szwarcberg J., Pill M. Allergic rhinitis, asthma, and rhinosinusitis: diseases of the integrated airway. J Manag Care Pharm 2004; 10(4): 310–317. DOI: 10.18553/jmcp.2004.10.4.310
11. Samitas K., Carter A., Kariyawasam H., Xanthou G. Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy 2018; 73(5): 993–1002. DOI: 10.1111/all.13373
12. Matucci A., Vultaggio A., Maggi E., Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res 2018; 19: 113. DOI: 10.1186/s12931–018–0813–0
13. Busse W., Corren J., Lanier B., McAlary M., Fowler-Taylor A., Cioppa G.D. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108(2): 184–190. DOI: 10.1067/mai.2001.117880
14. Gevaert P., Omachi T., Corren J., Mullol J., Han J., Lee S. et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020; 146(3): 595–605. DOI: 10.1016/j.jaci.2020.05.032.
15. Okubo K., Okano M., Sato N., Tamaki Y., Suzuki H., Uddin A., Fogel R. Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study. J Allergy Clin Immunol Pract 2020; 8(9): 3130–3140. DOI: 10.1016/j.jaip.2020.04.068
16. Aldinger J., Dobyns T., Lam K., Han J. The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther 2021; 21(9): 1143–1149. DOI: 10.1080/14712598.2021.1962282
17. Miglani A., Soler Z., Smith T., Mace J., Schlosser R. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol 2023; 13(2): 116–128. DOI: 10.1002/alr.23059
18. Hong H., Chen T., Yang Q., Sun Y., Chen F., Lou H. et al. Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai). ORL J Otorhinolaryngol Relat Spec 2023; 85(3): 128–140. DOI: 10.1159/000529918
19. Fokkens W., Viskens An-S., Backer V., Conti D., de Corso E., Gevaert P. et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps. Rhinology 2023; 61 (3): 194–202. DOI: 10.4193/Rhin22.489
20. Laidlaw T.M., Menzies-Gow A., Caveney S., Han J.K., Martin N., Israel E. et al. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR. J Asthma Allergy 2023; 16: 915–932. DOI: 10.2147/JAA.S413064
21. Gould H., Sutton B., Beavil A., Beavil R.L., McCloskey N., Coker H.A. et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol 2003; 21: 579–628. DOI: 10.1146/annurev.immunol.21.120601.141103
22. Dullaers M., De Bruyne R., Ramadani F., Gould H., Gevaert P., Lambrecht B. The who, where, and when of IgE in allergic airway disease. J Allergy Clin Immunol 2012; 129(3): 635–645. DOI: 10.1016/j.jaci.2011.10.029
23. Gevaert P., Nouri-Aria K., Wu H., Harper C.E., Takhar P., Fear D.J. et al. Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy 2013; 68(1): 55–63. DOI: 10.1111/all.12054
24. Gatto D., Brink R. The germinal center reaction. J Allergy ClinImmunol 2010; 126(5): 898–907. DOI: 10.1016/j.jaci.2010.09.007
25. De Schryver E., Devuyst L., Derycke L., Dullaers M., Van Zele T., Bachert C. et al. Local Immunoglobulin E in the Nasal Mucosa: Clinical Implications. Allergy Asthma Immunol Res 2015; 7(4): 321–331. DOI: 10.4168/aair.2015.7.4.321
Review
For citations:
Shabelnikova E.I., Pampura A.N., Asmanov A.I., Pivneva N.D. Prospects for assessing the level of tissue IgE and the use of biological therapy in children with polypous rhinosinusitis. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2024;69(4):11-15. (In Russ.) https://doi.org/10.21508/1027-4065-2024-69-4-11-15
Views:
315
Email this article 